1
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Passegué E, Jamieson CH, Ailles LE and
Weissman IL: Normal and leukemic hematopoiesis: Are leukemias a
stem cell disorder or a reacquisition of stem cell characteristics?
Proc Natl Acad Sci USA. 100:(Suppl 1). 11842–11849. 2003.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Warner JK, Wang JCY, Hope KJ, Jin L and
Dick JE: Concepts of human leukemic development. Oncogene.
23:7164–7177. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Huntly BJ and Gilliland DG: Leukaemia stem
cells and the evolution of cancer-stem-cell research. Nat Rev
Cancer. 5:311–321. 2005. View
Article : Google Scholar : PubMed/NCBI
|
5
|
Weissman I: Stem cell research: Paths to
cancer therapies and regenerative medicine. JAMA. 294:1359–1366.
2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Costello R, Mallet F, Chambost H, Sainty
D, Arnoulet C, Gastaut JA and Olive D: The immunophenotype of
minimally differentiated acute myeloid leukemia (AML-M0): Reduced
immunogenicity and high frequency of
CD34+/CD38− leukemic progenitors. Leukemia.
13:1513–1518. 1999. View Article : Google Scholar : PubMed/NCBI
|
7
|
van Rhenen A, Feller N, Kelder A, Westra
AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q,
Ossenkoppele GJ and Schuurhuis GJ: High stem cell frequency in
acute myeloid leukemia at diagnosis predicts high minimal residual
disease and poor survival. Clin Cancer Res. 11:6520–6527. 2005.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
9
|
Malaise M, Steinbach D and Corbacioglu S:
Clinical implications of c-Kit mutations in acute myelogenous
leukemia. Curr Hematol Malig Rep. 4:77–82. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wakita S, Yamaguchi H, Miyake K, Mitamura
Y, Kosaka F, Dan K and Inokuchi K: Importance of c-kit mutation
detection method sensitivity in prognostic analyses of
t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 25:1423–1432.
2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Park SH, Chi HS, Min SK, Park BG, Jang S
and Park CJ: Prognostic impact of c-KIT mutations in core binding
factor acute myeloid leukemia. Leuk Res. 35:1376–1383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Chao MP, Alizadeh AA, Tang C, Jan M,
Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL and Majeti R:
Therapeutic antibody targeting of CD47 eliminates human acute
lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Gerber JM, Smith BD, Ngwang B, Zhang H,
Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ,
et al: A clinically relevant population of leukemic CD34(+)CD38(–)
cells in acute myeloid leukemia. Blood. 119:3571–3577. 2012.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Meyer D, Seth S, Albrecht J, Maier MK, du
Pasquier L, Ravens I, Dreyer L, Burger R, Gramatzki M, Schwinzer R,
et al: CD96 interaction with CD155 via tts first Ig-like domain is
modulated by alternative splicing or mutations in distal Ig-like
domains. J Biol Chem. 284:2235–2244. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Fuchs A, Cella M, Giurisato E, Shaw AS and
Colonna M: Cutting edge: CD96 (tactile) promotes NK cell-target
cell adhesion by interacting with the poliovirus receptor (CD155).
J Immunol. 172:3994–3998. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hosen N, Park CY, Tatsumi N, Oji Y,
Sugiyama H, Gramatzki M, Krensky AM and Weissman IL: CD96 is a
leukemic stem cell-specific marker in human acute myeloid leukemia.
Proc Natl Acad Sci USA. 104:11008–11013. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Gramatzki M, Ludwig WD, Burger R, Moos P,
Rohwer P, Grünert C, Sendler A, Kalden JR, Andreesen R, Henschke F,
et al: Antibodies TC-12 (‘unique’) and TH-111 (CD96) characterize
T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid
leukemia. Exp Hematol. 26:1209–1214. 1998.PubMed/NCBI
|
18
|
Löwenberg B, Downing JR and Burnett A:
Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Wang PL, O'Farrell S, Clayberger C and
Krensky AM: Identification and molecular cloning of tactile. A
novel human T cell activation antigen that is a member of the Ig
gene superfamily. J Immunol. 148:2600–2608. 1992.PubMed/NCBI
|
20
|
Ebinger M, Witte KE, Ahlers J, Schӓfer I,
André M, Kerst G, Scheel-Walter HG, Lang P and Handgretinger R:
High frequency of immature cells at diagnosis predicts high minimal
residual disease level in childhood acute lymphoblastic leukemia.
Leuk Res. 34:1139–1142. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Witte KE, Ahlers J, Schӓfer I, André M,
Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P,
Handgretinger R, et al: High proportion of leukemic stem cells at
diagnosis is correlated with unfavorable prognosis in childhood
acute myeloid leukemia. Pediatr Hematol Oncol. 28:91–99. 2011.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Castor A, Nilsson L, Astrand-Grundström I,
Buitenhuis M, Ramirez C, Anderson K, Strömbeck B, Garwicz S,
Békássy AN, Schmiegelow K, et al: Distinct patterns of
hematopoietic stem cell involvement in acute lymphoblastic
leukemia. Nat Med. 11:630–637. 2005. View
Article : Google Scholar : PubMed/NCBI
|
23
|
Hong D, Gupta R, Ancliff P, Atzberger A,
Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, et
al: Initiating and cancer-propagating cells in TEL-AML1-associated
childhood leukemia. Science. 319:336–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Adams GP and Weiner LM: Monoclonal
antibody therapy of cancer. Nat Biotechnol. 23:1147–1157. 2005.
View Article : Google Scholar : PubMed/NCBI
|